Patent US5399347A successfully refreshed from Google Patents.
US5399347A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of treating rheumatoid arthritis with type II collagen
Assignee: BRONSON NUTRITIONALS LLC
•
Filing: 1992-09-25
•
Granted: 1995-03-21
•
Expires: 2012-09-25
Abstract
Abstract The present invention is directed to a method and pharmaceutical formulations for the treatment of autoimmune arthritis and animal models therefore in mammals, including humans, by the oral, enteral or by-inhalation administration of whole collagen protein or biologically active peptide fragments of collagen.
Inventors
- 👤 David E. Trentham
- 👤 Howard L. Weiner
- 👤 David A. Hafler
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 15:01
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/1703; A61K38/1709; A61K38/39; A61K39/00; A61K39/0005; A61K39/0008; C; C07; C07K; C07K14/00; C07K14/435; C07K14/46; C07K14/47; C07K14/4701; C07K14/4713; C07K14/78; A61K2039/54; A61K2039/541; A61K2039/542; A61K2039/543
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
57 words
A method for treating rheumatoid arthritis comprising oral administration of whole collagen II protein to a human in need of treatment, in an amount effective and for a period of time sufficient to decrease at least one clinical symptom selected from the group consisting of joint tenderness, joint swelling, morning stiffness, grip strength, and 50-foot walk time.
Claim 2
Independent Claim
57 words
A method for treating rheumatoid arthritis comprising oral administration of whole collagen II protein to a human in need of treatment, in an amount effective and for a period of time sufficient to decrease at least one clinical symptom selected from the group consisting of joint tenderness, joint swelling, morning stiffness, grip strength, and 50-foot walk time.
Claim 3
Dependent Claim
19 words
The method of claim 1, wherein the amount is within the range of about 0.1 to about 1 mg/day.
Claim 4
Dependent Claim
19 words
The method of claim 2 wherein the effective amount is within the range of about 0.1 to 0.5 mg/day.
Claim 5
Dependent Claim
19 words
The method of claim 2 wherein said type II collagen is dissolved in a physiologically acceptable aqueous acidic medium.
Claim 6
Independent Claim
41 words
A method for treating rheumatoid arthritis in a human in need of such treatment comprising oral administration to said human an amount of protein consisting of whole type II collagen, said amount being effective to decrease at least one arthritis symptom.
Claim 7
Independent Claim
41 words
A method for treating rheumatoid arthritis in a human in need of such treatment comprising oral administration to said human an amount of protein consisting of whole type II collagen, said amount being effective to decrease at least one arthritis symptom.
Claim 8
Independent Claim
39 words
A method for treating rheumatoid arthritis in a human in need of such treatment comprising oral administration of whole type II collagen in an amount effective to suppress autoimmune response in at least one afflicted joint of said human.
Claim 9
Independent Claim
39 words
A method for treating rheumatoid arthritis in a human in need of such treatment comprising oral administration of whole type II collagen in an amount effective to suppress autoimmune response in at least one afflicted joint of said human.
Claim 10
Independent Claim
44 words
A method for treating rheumatoid arthritis comprising oral administration of whole collagen II protein to a human in need of such treatment, in an amount effective and for a period of time sufficient to substantially stabilize the arthritic condition while discontinuing cytotoxic drug administration.
Claim 11
Independent Claim
44 words
A method for treating rheumatoid arthritis comprising oral administration of whole collagen II protein to a human in need of such treatment, in an amount effective and for a period of time sufficient to substantially stabilize the arthritic condition while discontinuing cytotoxic drug administration.
References Cited (Backward Citations)
US4804745A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-03-20 | 1998-09-19 | 1999-03-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-03-20 | 2002-09-19 | 2003-03-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-03-20 | 2006-09-19 | 2007-03-21 | $7700.00 | Window Closed / Lapsed |